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In the future, everyone will be
boring. That was the surprising
message from the science-fiction
movie Gattaca, in which Ethan
Hawke and Uma Thurman stumbled
around a world in which genetically
perfect humans are the norm. 
Although Gattaca’s script was
profoundly snooze-inducing, its
premise of widespread germline
engineering is starting to look
reasonable. “I certainly think it will
happen,” says Princeton geneticist
Lee Silver. “The only question is
when.” Gregory Stock, director of the
University of California, Los Angeles,
Program on Medicine, Technology
and Society, co-organized a 1998
symposium called “Engineering the
Human Germline,” the first major
forum on human germline
engineering. “The range of
discussion,” he says, “was whether it
would happen in 20 years or 100
years, but not that it wouldn’t occur.”
The general public remains, for
the most part, blissfully unaware of
this impending revolution. But
discussion in academia has started
because the technologies for
achieving germline engineering are
rapidly being assembled. “So often
technologies are created for one
purpose and used for another,” says
Silver. This is certainly the case with
germline engineering. Genes suitable
for transfer are coming from the
human genome project. Stem cells to
receive the genes are being
characterized by companies like
Geron Corporation (Menlo Park,
California) and Advanced Cell
Technology, Inc. (Worcester,
Massachusetts), ostensibly to create
transplantable cells and tissues. And
artificial minichromosomes to carry
all the genes are being created by two
companies — Chromos Molecular
Systems Inc. (Burnaby, British
Columbia, Canada) and Athersys Inc.
(Cleveland, Ohio) — both of which
swear they have no interest or intent
in the area of germline engineering. 
But others are showing plenty of
interest. “The only way [germline
engineering] will ever be significant is
through the use of synthetic
minichromosomes,” says Stock. “This
is the only way you can produce a
technology that is sufficiently
reproducible, safe and reliable.”
Artificial minichromosomes may
end up as carriers for germline
gene therapy.
An innocent start
Huntington Willard was and still is
interested in something far less
controversial than germline
engineering. But to explore his
interest — the basic requirements for
human chromosome functioning and
segregation — he wanted to make a
synthetic human chromosome
(Figure 1). Willard, now at Case
Western Reserve University in
Cleveland, Ohio, could only look on
enviously in 1983 as Jack Szostak and
Andrew Murray (then at Harvard
Medical School in Boston,
Massachusetts) put together
selectable genes, origins of DNA
replication, a centromere, and
telomeres to create a yeast artificial
chromosome (YAC). 
For Willard, the stumbling block
was the centromere — the DNA
sequence that specifies attachment to
the mitotic spindle. In budding yeast
the centromere is a conserved 120
base pairs of DNA, but the search for a
comparable sequence in humans was
proving frustrating. By the late 1980s,
Willard had started studying the
repetitive satellite DNA characteristic
of human centromeres, but “nobody
at that time took seriously the idea
that those were the centromere
sequences,” he says. Slowly satellite
DNA gained favor, and in 1997
Willard published his killer result:
transfection of a mixture of genomic
DNA, alpha satellites and telomeres
yielded lots of chromosome insertions
and truncations, but at least one de
novo synthetic minichromosome.
Athersys had its founding technology. 
The Hungarian connection
In January of the same year, Chromos
opened its doors in British Columbia.
The company based itself on some
rather obscure science from Gyula
Hadlaczky (Hungarian Academy of
Sciences, Szeged, Hungary).
Hadlaczky had isolated a lambda
clone of what he thought were
candidate centromere sequences. He
transfected the sequences into mouse
cells and, lo and behold, got the
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Figure 1
Artificial chromosomes. (a) A mouse artificial
chromosome (stained for mouse major
satellite DNA, in green) created using the
Chromos technology, in a spread of normal
human chromosomes. (b) A smaller human
synthetic chromosome created by Athersys.
Images courtesy of Chromos and Athersys.
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desired minichromosome. But the
new chromosome had formed through
an unusual pathway. Weak homology
between the lambda sequence and
rDNA near a centromere had targeted
the introduced sequence to this
region. Somehow this insertion
activated a postulated megareplicator
sequence. Amplification and
centromere duplication formed a
dicentric chromosome that broke,
yielding a new minichromosome.
Chromos has repeated the
procedure (although targeting now
with rDNA) to generate 40–60 Mb
chromosomes. “The event that we
are triggering is reproducible, but we
get different amplification events,”
says Chromos director of projects Carl
Perez. The company now plans to
add recombination sites for systems
such as FLP/FRT or Cre/Lox to
these existing chromosomes, and use
the sites to shuttle in new genes.
“That will speed up the production
of a new chromosome from 6 months
to 4–5 weeks,” says Perez.
The first application for the
chromosomes is protein production in
cell culture, in a collaboration with
Boehringer Ingelheim. The Chromos
vector has allowed more rapid and
extensive amplification of gene copy
number and therefore protein output.
For production of therapeutic
proteins in the milk of domestic
animals, Perez hopes to beat the
transgenic cloning crowd in cost and
speed. To establish each new founder
for cloning, a gene of interest must
undergo random integration, which
often leads to position effects that
reduce transcription. The Chromos
approach should avoid position effects,
and allow the introduction of multiple,
large genes. Mammary-specific
expression can be pre-selected in
mice. The cloners, meanwhile, cannot
see expression of their genes in their
transfected fetal cells, and so must
wait to see if the promoter turns on in
an expensive cloned cow. 
Gene therapy, but somatic only, please
Chromos is interested initially in
localized gene therapy for indications
such as rheumatoid arthritis, using in-
licensed genes that have yet to be
identified. Delivery will be a challenge,
but Chromos will try a combination of
lipids and electro- or sonoporation. 
Delivery problems may reflect
difficulties in penetrating the cell,
preventing DNA degradation, or
establishing centromere proteins on
naked DNA — a task that normal
cells are never faced with. But
artificial chromosomes offer the
advantage, compared to viral gene
delivery, of greater persistence for
treating chronic diseases.
Athersys will focus initially on ex
vivo gene therapy and is collaborating
with Gene-Cell Inc. (Houston,
Texas) to test a rapid microinjection
delivery system. They expect to
enter animal trials very soon, and the
clinic in perhaps two years. 
Early ambition
Athersys CEO Gil Van Bokkelen
helped form the company out of
Willard’s laboratory, and gives the
impression that his feverish energy
has been driving it ever since. No
warm-ups for Van Bokkelen; his first
declaration after “hello” is to state
that “our long-term strategic goal is to
become a fully integrated company.”
The synthetic minichromosome
technology, he says, “is something we
are very excited about, but it’s a
relatively small part of the company.”
A number of researchers,
including Howard Cooke (Western
General Hospital, Edinburgh),
express doubts about the
commercialization of the technology.
“I think it’s some way away from
practical application,” he says. The
minichromosome technology has,
however, moved significantly beyond
the work described in Willard’s 1997
publication. The transfection of
unassembled DNA fragments “was a
way to prove a point,” says Van
Bokkelen. “Now we work with fully
defined pre-fabricated units.” The
assembly platform is bacterial
artificial chromosomes (BACs),
which Cooke is also investigating
with Boehringer Ingelheim.
The future is Ethan
Chromos constructs are stable in both
founder and progeny mice, but Perez
says of human germ line gene therapy:
“We wouldn’t do it. It’s not in our code
of ethics to make a better person.” Van
Bokkelen is no less emphatic. “It’s a
no-no, an absolute mistake,” he says.
Serious genetic diseases can
increasingly be managed by embryo
selection, they say, and no one has a
good idea of how a human with an
extra chromosome could mate with
an unaltered human without causing
genetic complications. 
But those protestations and more
were faced down by participants at the
UCLA symposium. Mario Capecchi
(University of Utah, Salt Lake City)
proposed a recombination system to
flip out the centromere in germ cells.
“You wouldn’t want to keep [the
chromosomes] anyway if the
technology is advancing,” noted Stock. 
But what we would we put in? “If
you add in a new gene you don’t
really know how it will work,” says
Silver. “So you add in a gene that
already exists, like a gene that some
people have that gives HIV
resistance. It’s hard to imagine a
government stopping parents giving
their children something that other
children already receive naturally.”
These gene variants — including
one that makes trained muscle more
mechanically efficient (see Nature,
403, p614) — are a start. But the real
impetus, Silver says, will come with
genes that reduce susceptibility to
major diseases. It will take many years
to accumulate these genes, says Silver,
but when enough can be piled onto a
high capacity artificial chromosome,
parents will demand it. “If there are
meaningful enhancements they will
almost certainly be adopted by some
people,” says Stock. “And then there
will be intense competitive pressure
for the rest of us to join in.” 
Put on your suit, Ethan. We’ve
arrived at Gattaca.
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